Premium
Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab
Author(s) -
Toth C.,
Martin L.,
Morrish W.,
Coutts S.,
Parney I.
Publication year - 2007
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2007.00870.x
Subject(s) - neurosarcoidosis , infliximab , medicine , refractory (planetary science) , magnetic resonance imaging , surgery , sarcoidosis , radiology , disease , physics , astrobiology
Background – Neurosarcoidosis is often a devastating, refractory condition without definite pharmacotherapies beyond corticosteroids. Aim – To describe a case of steroid‐refractory neurosarcoidosis with a marked clinical and radiological response to infliximab. Methods – We describe the case of a young female patient with biopsy‐proven neurosarcoidosis leading to gait failure. She described significant corticosteroid‐related side effects without clinical response to the therapy. Infliximab therapy was considered as a possible rescue medication. Results – Within months of starting intravenous infliximab therapy, she regained her ability to walk and magnetic resonance imaging identified significant improvements over a sustained course of infliximab therapy, including loss of enhancing nodules and loss of meningeal enhancement. Conclusion – Mounting evidence suggests that infliximab is a valuable pharmacological agent in the management of patients with refractory and disabling neurosarcoidosis. Controlled studies of infliximab in this condition are needed.